Trial · NCT03289910
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With a Response | Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) | Participants with a response | 5 | Participants | |
| Number of Participants With a Response | Arm B (Topotecan Hydrochloride, Carboplatin) | Participants with a response | 4 | Participants | |
| Number of Participants With a Response | Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) | Participants who did not have a response | 11 | Participants | |
| Number of Participants With a Response | Arm B (Topotecan Hydrochloride, Carboplatin) | Participants who did not have a response | 5 | Participants | |
| The Highest Grade Adverse Event Experienced | Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) | Grade 5 Adverse Events | 0 | Participants | |
| The Highest Grade Adverse Event Experienced | Arm B (Topotecan Hydrochloride, Carboplatin) | Grade 5 Adverse Events | 1 | Participants | |
| The Highest Grade Adverse Event Experienced | Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) | Grade 4 Adverse Events | 14 | Participants | |
| The Highest Grade Adverse Event Experienced | Arm B (Topotecan Hydrochloride, Carboplatin) | Grade 4 Adverse Events | 8 | Participants | |
| The Highest Grade Adverse Event Experienced | Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) | Grade 3 Adverse Events | 2 | Participants | |
| The Highest Grade Adverse Event Experienced | Arm B (Topotecan Hydrochloride, Carboplatin) | Grade 3 Adverse Events | 0 | Participants | |
| Number of Participants Without Disease at Study Completion | Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) | 3 | Participants | ||
| Number of Participants Without Disease at Study Completion | Arm B (Topotecan Hydrochloride, Carboplatin) | 3 | Participants | ||
| Duration of Disease-free Survival | Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) | 120 | 95% Confidence Interval 37 to 137 | days | |
| Duration of Disease-free Survival | Arm B (Topotecan Hydrochloride, Carboplatin) | 89 | 95% Confidence Interval 27 to 137 | days | |
| Number of Participants Still Alive at Study Completion | Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) | 5 | Participants | ||
| Number of Participants Still Alive at Study Completion | Arm B (Topotecan Hydrochloride, Carboplatin) | 5 | Participants | ||
| Duration of Overall Survival at the Time of Study Completion | Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) | 83 | 95% Confidence Interval 74 to 295 | Days | |
| Duration of Overall Survival at the Time of Study Completion | Arm B (Topotecan Hydrochloride, Carboplatin) | 123 | 95% Confidence Interval 82 to 295 | Days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03289910/results